Building robust and scalable systems

In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Kevin Orfan, President at Sharp. Kevin has been in the pharmaceutical and medical device industry for over 30 years and has incredible experience in the contract manufacturing space. He began his pharma career at Abbott Laboratories before moving to Hospira and then Pfizer CentreOne. He joined Sharp as president in 2019 and now oversees its global operations.

 

Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with guest Kevin Orfan speaking on the importance of building robust and scalable systems and processes in a fast growing contract packaging company, especially in the current climate of the pandemic. Kevin talks about the challenges in keeping up with the rapid, global demand of new, large molecule drug products and the increasing complexity they bring. He shares how he maintains a solid work ethic by always having a plan, knowing what he can control and focusing on the value-add factors in a business as a top priority. Lastly he speaks about the direct-to-patient trend he is seeing in the industry as pharmaceutical companies become more willing to carry out clinical trial work in patient's homes.

 

Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also love a positive rating! Molecule to Market is sponsored and funded by ramarketing, an international content, design and digital agency that helps companies get noticed, raise profile and generate leads in life sciences.